Myeloproliferative Neoplasms Clinical Trial

Extension Study of Bomedemstat (IMG-7289) in Patients With Myeloproliferative Neoplasms

Summary

This is a multi-center, open-label extension study to assess the long-term safety and efficacy of bomedemstat administered orally once daily in patients with an MPN who participated in a prior bomedemstat study such as, but not limited to, IMG-7289-CTP-102 and IMG-7289-CTP-201 (referred to hereafter as 'feeder studies').

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Completed at least one Treatment Period (TP) in a prior bomedemstat MPN protocol (such as, but not limited to, IMG-7289-CTP-102 or IMG-7289-CTP-201).
In the estimation of the Investigator, the risk-benefit favors continued dosing with bomedemstat.

Exclusion Criteria:

Ongoing participation in another investigational study (except observational studies).
A history of non-compliance in a prior bomedemstat study (excluding dose suspensions that were medically warranted).
Current use of a prohibited medication (e.g., romiplostim).
Medical, psychiatric, cognitive, or other conditions that, in the Investigator's opinion, compromise the patient's safety, ability to give informed consent, or comply with the trial protocol.
Females who are pregnant or breastfeeding or plan to become pregnant or breastfeed during the study.
Women of childbearing potential (WOCBP) and fertile men unwilling to agree to use an approved method of contraception from time of enrollment until 14 days after last bomedemstat dose.

Study is for people with:

Myeloproliferative Neoplasms

Phase:

Phase 2

Estimated Enrollment:

80

Study ID:

NCT05223920

Recruitment Status:

Enrolling by invitation

Sponsor:

Imago BioSciences,Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 17 Locations for this study

See Locations Near You

University of Miami Leonard M. Miller
Miami Florida, 33136, United States
University of Michigan
Ann Arbor Michigan, 48109, United States
Cleveland Clinic Foundation
Cleveland Ohio, 44195, United States
UMPC Hillman Cancer Center
Pittsburgh Pennsylvania, 15232, United States
Fred Hutchinson Cancer Center
Seattle Washington, 98109, United States
Royal Prince Alfred Hospital
Camperdown New South Wales, 2050, Australia
Royal North Shore Hospital
Saint Leonards New South Wales, 2065, Australia
Gold Coast Hospital and Health Service
Southport Queensland, 4215, Australia
Royal Adelaide Hospital
Adelaide South Australia, 5000, Australia
Universittsklinikum Essen
Essen , 45147, Germany
Queen Mary Hospital
Hong Kong , , Hong Kong
Ospedale di Circolo-a Fondazione Macchi
Varese VA, 2100, Italy
Azienda Ospedaliera SS. Antonio
Alessandria , 15121, Italy
Azienda Ospedaliero Universitaria di Bologna
Pavia , 27100, Italy
Middlemore Clinical Trials
Papatoetoe Aukland, 2025, New Zealand
Waitemata District Health Board
Takapuna Aukland, 0622, New Zealand
University College London Hospitals NHS Foundation Trust
London , NW1 1, United Kingdom
Guy's and Saint Thomas' NHS Foundation Trus
London , SE1 9, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Myeloproliferative Neoplasms

Phase:

Phase 2

Estimated Enrollment:

80

Study ID:

NCT05223920

Recruitment Status:

Enrolling by invitation

Sponsor:


Imago BioSciences,Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.